Orchestra Medical Ventures
Orchestra Medical Ventures, founded in 2000 and based in New Hope, Pennsylvania, is an investment firm focused on the medical technology sector. The firm utilizes a unique strategy that emphasizes collaboration with leading physicians and experienced technical and business professionals to identify and address significant unmet clinical needs. By immersing itself in high-value clinical areas, Orchestra analyzes opportunities for technological innovations aimed at enhancing patient outcomes while reducing costs and complications. The firm not only invests in but also actively develops optimal device solutions tailored to these identified needs. Orchestra Medical Ventures builds on the foundation laid by its predecessor, Accelerated Technologies, Inc., which operated as a medical device accelerator. This approach aims to increase the likelihood of successful investments in medical technology by aligning the interests of physicians, management, and investors throughout the development process.
Top Stages
2 past transactions
Motus GI Holdings
Venture Round in 2016
Motus GI Holdings, Inc. is a medical technology company based in Fort Lauderdale, Florida, with operations in the United States and Israel. The company specializes in developing endoscopy solutions aimed at improving clinical outcomes and reducing costs associated with gastrointestinal conditions. Its primary product, the Pure-Vu System, is designed to assist in the cleaning of poorly prepared colons during colonoscopy procedures, thereby enhancing the overall patient experience and aiding in the early detection of colorectal cancer and other gastrointestinal diseases. The Pure-Vu System has received clearance from the U.S. Food and Drug Administration and holds CE marking for use in the European Economic Area.
Mitralign
Venture Round in 2012
Mitralign is a privately held medical device company based in a suburb of Boston, Massachusetts. It specializes in developing catheter-based technologies for the percutaneous treatment of functional mitral regurgitation, a global and life-threatening cardiac condition. The company's innovative Mitralign system mimics surgical annuloplasty by delivering a series of implants directly into the mitral annulus via a catheter, reducing its size and improving valve function. Mitralign is backed by top-tier venture capitalists and has strategic investments from major cardiovascular device companies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.